InspireMD, Inc. (NYSEMKT:NSPR) Files An 8-K Termination of a Material Definitive Agreement
Item 1.02 Termination of a Material Definitive Agreement.
On March 21, 2017, InspireMD, Inc. (the Company) paid down the
remaining $1.2 million balance under the Companys Loan and
Security Agreement (the Loan Agreement), dated as of October 23,
2013, with Hercules Technology Growth Capital, Inc. (Hercules).
All liens and other security interests granted to Hercules by the
Company and its subsidiaries in connection with the Loan
Agreement were terminated upon such payment. The key terms of the
Loan Agreement and the amendments to the Loan Agreement were
disclosed on the Companys Current Reports on Form 8-K, filed with
the Securities and Exchange Commission on October 25, 2013 and
June 14, 2016, respectively.
Item 8.01 Other Events.
On March 22, 2017, the Company announced its repayment of the
remaining balance on the Loan Agreement with Hercules. A copy of
the press release announcing these events is attached as Exhibit
99.1 to this Current Report on Form 8-K and is hereby
incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |
| 99.1 | Press release, dated March 22, 2017 |
About InspireMD, Inc. (NYSEMKT:NSPR)
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device. InspireMD, Inc. (NYSEMKT:NSPR) Recent Trading Information
InspireMD, Inc. (NYSEMKT:NSPR) closed its last trading session up +0.10 at 1.03 with 557,946 shares trading hands.